Published in Microvasc Res on July 01, 2003
Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One (2010) 1.08
Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. Thromb Res (2008) 0.90
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation. Mol Cancer Ther (2015) 0.75
Expression of protease-activated receptor 1 and 2 and anti-tubulogenic activity of protease-activated receptor 1 in human endothelial colony-forming cells. PLoS One (2014) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Drug discovery. Repurposing with a difference. Science (2009) 2.97
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol (2006) 2.74
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest (2007) 1.98
Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood (2003) 1.96
Admission angiopoietin levels in children with septic shock. Shock (2007) 1.82
Preeclampsia: a renal perspective. Kidney Int (2005) 1.82
Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem (2007) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer (2012) 1.80
Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. Clin Chem (2013) 1.71
roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.69
Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock (2008) 1.62
Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun (2005) 1.59
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia (2011) 1.45
Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens (2002) 1.38
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem (2005) 1.36
Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol (2002) 1.34
Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab (2004) 1.34
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol (2013) 1.30
Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion. Mol Cell Biol (2005) 1.29
Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J (2007) 1.27
Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol (2013) 1.24
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer (2005) 1.19
A critical role for calponin 2 in vascular development. J Biol Chem (2005) 1.14
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology (2007) 1.13
Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J (2004) 1.10
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res (2009) 1.09
Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res (2005) 1.09
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol (2012) 1.08
Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol (2013) 1.07
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res (2007) 1.03
Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J (2009) 1.02
Nephrocan, a novel member of the small leucine-rich repeat protein family, is an inhibitor of transforming growth factor-beta signaling. J Biol Chem (2006) 1.01
Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. J Am Soc Nephrol (2013) 1.01
In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst (2003) 1.00
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer (2010) 0.98
Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem (2004) 0.96
A novel endothelial-specific heat shock protein HspA12B is required in both zebrafish development and endothelial functions in vitro. J Cell Sci (2006) 0.96
Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension (2004) 0.95
Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One (2010) 0.95
Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. Mol Cell Biol (2004) 0.94
Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem Pharmacol (2013) 0.94
Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice. Hepatology (2013) 0.94
Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res (2006) 0.93
Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem Biophys Res Commun (2008) 0.93
Critical roles of CD146 in zebrafish vascular development. Dev Dyn (2005) 0.93
Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol (2004) 0.92
Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol (2003) 0.90
Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. Thromb Res (2008) 0.90
Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res (2007) 0.89
Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett (2009) 0.87
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog (2011) 0.86
6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun (2013) 0.83
Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int (2008) 0.83
A small-molecule screening strategy to identify suppressors of statin myopathy. ACS Chem Biol (2011) 0.83
Cellular actions and signaling by endostatin. Crit Rev Eukaryot Gene Expr (2002) 0.82
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res (2014) 0.81
Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future Oncol (2015) 0.81
Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res (2012) 0.79
Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck (2014) 0.78
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer. Breast Cancer Res Treat (2014) 0.76
A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium. J Urol (2002) 0.76
A refined understanding of immunosuppressives and cancer risk. Kidney Int (2003) 0.75
One-step purification of soluble recombinant human 6-phosphogluconate dehydrogenase from Escherichia coli. Protein Expr Purif (2013) 0.75